´╗┐
 Return to QS81 Overview

Inflammatory bowel disease [QS81]

Measuring the use of this guidance

Statement: 4

People receiving drug treatment for inflammatory bowel disease are monitored for adverse effects.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: The percentage of all adult patients receiving treatment with biological therapies for whom an adverse reaction was recorded at 3 month follow-up.
Data collection end: February 2016
10%
Number that met the criteria: 82 / 855
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: The percentage of all paediatric patients receiving treatment with biological therapies for whom an adverse reaction was recorded at initial treatment.
Data collection end: February 2016
1%
Number that met the criteria: 4 / 278
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: Proportion of all paediatric patients receiving treatment with biological therapies for whom an adverse reaction was recorded at 3 month follow-up.
Data collection end: February 2016
5%
Number that met the criteria: 6 / 121
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: The number of adverse events reported because of drug treatment for inflammatory bowel disease.
What was measured: Proportion of patients taking biological therapy with an adverse reaction recorded during initial treatment.
Data collection end: February 2015
3%
Number that met the criteria: 97 / 3531
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: The number of adverse events reported because of drug treatment for inflammatory bowel disease.
What was measured: Proportion of patients taking biological therapy with an adverse reaction recorded during initial treatment.
Data collection end: February 2016
4%
Number that met the criteria: 117 / 2722
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.



 Return to QS81 Overview